Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Clinical trial NCT05005403 · RECRUITING

Trial details

NCT number

NCT05005403

Sponsor

AbbVie

Status

RECRUITING

Phase

Phase 1

Study type

INTERVENTIONAL

Start date

2021-11-01

Primary completion

2027-07-01

Enrollment

694

View on ClinicalTrials.gov